Remove Article Remove Heart Disease Remove Innovation
article thumbnail

Artificial intelligence in heart valve disease: diagnosis, innovation and treatment. A state-of-the-art review

The British Journal of Cardiology

In recent years, artificial intelligence (AI) has been used to improve the precision of valvular heart disease diagnosis and treatment. This review article explores the various potential applications of AI in the diagnosis and treatment of valvular heart disease in more detail.

article thumbnail

Application of adipose-derived stem cells in ischemic heart disease: theory, potency, and advantage

Frontiers in Cardiovascular Medicine

Adipose-derived mesenchymal stem cells (ASCs) represent an innovative candidate to treat ischemic heart disease (IHD) due to their abundance, renewable sources, minor invasiveness to obtain, and no ethical limitations.

article thumbnail

Congenital heart disease research landscape in the Arab world: a 25-year bibliometric review

Frontiers in Cardiovascular Medicine

Background While research on congenital heart disease has been extensively conducted worldwide, comprehensive studies from developing countries and the Arab world remain scarce. Aim This study aims to perform a bibliometric review of research on congenital heart disease in the Arab world from 1997 to 2022.

article thumbnail

Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

DAIC

Widely recognized for pioneering innovative concepts and techniques in TAVR, Tang has set contemporary standards in the field. His impressive international academic collaborations include the establishment of multiple global registries and the training of heart teams in structural heart imaging and procedures worldwide.

TAVR 105
article thumbnail

Cover Story | New Frontiers in Heart Failure Care: Innovations Reshaping Treatment

American College of Cardiology

The idea that obesity increases the risk of heart failure seems like an obvious conclusion. After all, as the Framingham Heart Study clearly showed, obesity and overweight are significantly associated with a higher risk of hypertension, angina and coronary heart disease.

article thumbnail

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

DAIC

Cleerly, a digital healthcare company focused on heart disease, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging. In Press European Heart Journal CV Imag 2024.This

article thumbnail

Top 10 AI Cardiometabolic Startups to Watch in 2025 

Cardiometabolic Health Congress

These innovative companies leverage AI to develop cutting-edge diagnostic tools, predictive analytics, and personalized medicine approaches. These companies are at the forefront of innovation, driving improvements in patient outcomes and reshaping the future of healthcare delivery.